Supplements OLD
Advanced Practitioners in Hematology and Oncology: A Call to Action
This supplement to JADPRO, produced in collaboration with the Advanced Practitioner Society for Hematology and Oncology (APSHO) Professional Development and Leadership Committee, is part of an initiative within the APSHO strategic plan to address the continued needs of AP leaders and the APs they support.
Visit APSHO.org for resources developed by the committee and a forum to discuss professional development and leadership issues with the advanced practice community.
Editorial
Advanced Practitioners in Hematology and Oncology: A Call to Action
Sandra Kurtin, PhD, ANP-BC, AOCN®, FAPO, Guest Editor
Read MoreResearch and Scholarship
Advanced Practitioners in Hematology and Oncology: State of the Workforce
Sandra Kurtin,(1) PhD, ANP-BC, AOCN®, FAPO, Carolyn Grande,(2) CRNP, AOCNP®, Megan May,(3) PharmD, BCOP, FAPO, FHOPA, Andrea Edwards,(4) PA-C, Steven Wei,(5) EdD, MS, MPH, PA-C, DFAPPA, Brianna Hoffner,(6) MSN, ANP-BC, AOCNP®, FAPO, and Wendy Vogel,(7) MSN, FNP, AOCNP®, FAPORead MoreResearch and Scholarship
The Value of the Advanced Practitioner in Hematology and Oncology: Establishing Benchmarks
Sandra Kurtin,(1) PhD, ANP-BC, AOCN®, FAPO, Mailey L. Wilks,(2) DNP, APRN-CNP, Heather Koniarczyk,(2) MSN, APRN-CNP, AOCNP®, Nicole Deline,(3) MSN, APRN, FNP-C, AOCNP®, Sara Toth,(4) FNP-C, AOCNP®, AGN-BC, Andrea Edwards,(5) PA-C, Scott Rowley,(6) DNP, APRN-CNP, AOCNP®, Jason Astrin,(7) DMSc, MBA, PA-C, DFAAPA, and Wendy Vogel,(8) MSN, FNP, AOCNP®, FAPORead MoreReview Article
Understanding Advanced Practitioner Prescriptive Privileges for Anticancer Therapies: A National Survey
Archana Ajmera,(1) MSN, ANP-BC, AOCNP®, Leigh Boehmer,(2) PharmD, BCOP, Christa Marie Braun-Inglis,(3) DNP, APRN, FNP-BC, AOCNP®, Brianna Hoffner,(4) MSN, ANP-BC, AOCNP®, FAPO, Maria Matta,(2) MPH, and Rana R. McKay,(1) MDRead MoreReview Article
Advanced Practitioners as Agents of Change: Leveraging Quality Improvement to Improve Practice
Sandra Kurtin,(1) PhD, ANP-BC, AOCN®, FAPO, Andrea Edwards,(2) PA-C, Heather Koniarczyk,(3) MSN, APRN-CNP, AOCNP®, Camille Petraitis,(4) DNP, FNP-BC, Lisa Nodzon,(5) PhD, APRN, AOCNP®, Nicole Deline,(6) MSN, APRN, FNP-C, AOCNP®, Tajuana Bradley,(7) FNP-BC, Megan May,(8) PharmD, BCOP, FAPO, FHOPA, Molly Thompson-Coffey,(9) Jessica Tamasi,(9) and Wendy Vogel,(10) MSN, FNP, AOCNP®, FAPORead MoreReview Article
Role of the Advanced Practitioner in Clinical Research
Christa Marie Braun-Inglis,(1) DNP, APRN, FNP-BC, AOCNP®, Brianna Hoffner,(2) MSN, ANP-BC, AOCNP®, FAPO, Lisa Kottschade,(3) APRN, MSN, CNP, FAPO, Erin Pierce,(4) MSN, APRN, FNP-C, and Sandra Kurtin,(5) PhD, ANP-BC, AOCN®, FAPORead MoreReview Article
APSHO Oncology/Hematology Advanced Practitioner Compensation Survey
Wendy Vogel,(1) MSN, FNP, AOCNP®, FAPO, Yi Lisa Hwa,(2) APRN, DNP, CNP, FAPO, Lisa Kottschade,(2) APRN, MSN, CNP, FAPO, and Megan May,(3) PharmD, BCOP, FAPO, FHOPARead MoreASCO Highlights and Commentary:
The Advanced Practitioner Perspective
This supplement to JADPRO provides an overview of important abstracts that were presented at the 2023 ASCO Annual Meeting, along with expert commentary that aims to contextualize the information presented at ASCO for the advanced practitioner (AP).
Visit jadpro.com/highlights to view short videos featuring the AP commentators discussing these important abstracts.
Guest Editors
Andrew S. Guinigundo, MSN, RN, CNP, ANP-BC
Cincinnati Cancer Advisors
Lisa Kottschade, APRN, MSN, CNP, FAPO
Mayo Clinic
Oxana Megherea, PharmD, BCOP
Hospital of the University of Pennsylvania
Meeting Report
Racial Disparities, Advanced Ovarian Cancer, and HER2 Expression: 2023 ASCO Annual Meeting Highlights for the Advanced Practitioner
Andrew S. Guinigundo, MSN, RN, CNP, ANP-BCRead MoreMeeting Report
Early-Stage Breast Cancer, EGFR-Mutated NSCLC, and High-Risk Melanoma: 2023 ASCO Annual Meeting Highlights for the Advanced Practitioner
Lisa Kottschade, APRN, MSN, CNP, FAPORead MoreMeeting Report
Relapsed/Refractory Multiple Myeloma, DLBCL, and CLL: 2023 ASCO Annual Meeting Highlights for the Advanced Practitioner
Oxana Megherea, PharmD, BCOPRead MoreAdvanceS in Biomarker-Driven Therapy: Implications for Advanced Practitioners
This supplement provides advanced practitioners with a better understanding of biomarker testing in oncology and how it can inform selection of therapy, as well as practical tools to optimize outcomes.
Accompanying this supplement is a patient education guide on understanding biomarker testing, as well as an interactive video called, “Biomarker Testing in Cancer: Empowering Patients for Important Discussions With the Care Team,” which can be found at patiented.jadpro.com/biomarker.
Guest Editors
Donald C. Moore, PharmD, BCPS, BCOP, DPLA, FCCP
Levine Cancer Institute, Atrium Health
Andrew S. Guinigundo, MSN, RN, CNP, ANP-BC
Cincinnati Cancer Advisors
Review Article
Revolutionizing Cancer Treatment: Harnessing the Power of Biomarkers to Improve Patient Outcomes
Donald C. Moore,(1) PharmD, BCPS, BCOP, DPLA, FCCP, and Andrew S. Guinigundo,(2) MSN, RN, CNP, ANP-BCRead MoreReview Article
Biomarker-Driven Oncology Clinical Trials: Novel Designs in the Era of Precision Medicine
Donald C. Moore,(1) PharmD, BCPS, BCOP, DPLA, FCCP, and Andrew S. Guinigundo,(2) MSN, RN, CNP, ANP-BCRead MoreReview Article
The Role of Biomarkers in Guiding Clinical Decision-Making in Oncology
Donald C. Moore,(1) PharmD, BCPS, BCOP, DPLA, FCCP, and Andrew S. Guinigundo,(2) MSN, RN, CNP, ANP-BCRead MoreReview Article
The Advanced Practitioner’s Role in the Rapidly Evolving Landscape of Precision Medicine
Donald C. Moore,(1) PharmD, BCPS, BCOP, DPLA, FCCP, and Andrew S. Guinigundo,(2) MSN, RN, CNP, ANP-BCRead MoreMultiple myeloma and plasma cell disorders: update on diagnosis, prognosis, treatment, and supportive care
This supplement to JADPRO has been developed by members of the International Myeloma Foundation (IMF) Nurse Leadership Board.
This CE-certified supplement is jointly provided by
Guest Editors
Beth Faiman, PhD, MSN, APRN-BC, AOCN, BMTCN, FAAN
Cleveland Clinic Taussig Cancer Insitute
Tiffany Richards, PhD, ANP-BC, AOCNP
The University of Texas MD Anderson Cancer Center
This certified activity is supported by educational grants from AbbVie, Inc.; Bristol-Myers Squibb Company; GlaxoSmithKline; Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC; Karyopharm Therapeutics; Legend Biotech; Oncopeptides, Inc.; Sanofi Genzyme; and Takeda Pharmaceuticals U.S.A., Inc.
Continuing Education
Continuing Education Information: Multiple Myeloma and Plasma Cell Disorders: Update on Diagnosis, Prognosis, Treatment, and Supportive Care
Read MoreEditorial
Introduction
Beth Faiman, PhD, MSN, APRN-BC, AOCN®, BMTCN, FAAN, and Tiffany Richards, PhD, ANP-BC, AOCNP®Read MoreGrand Rounds
A Focus on Newly Diagnosed Multiple Myeloma
Kevin Brigle,(1) PhD, ANP, Daniel Verina,(2) DNP, RN, ACNP-BC, and Beth Faiman,(3) PhD, MSN, APRN-BC, AOCN®, BMTCN, FAANRead MoreGrand Rounds
A Focus on Relapsed Multiple Myeloma
Kimberly Noonan,(1) DNP, ANP-BC, AOCN®, Sandra Rome,(2) RN, MN, AOCN®, CNS, and Beth Faiman,(3) PhD, MSN, APRN-BC, AOCN®, BMTCN, FAANRead MoreGrand Rounds
A Focus on Special Populations in Relapsed Multiple Myeloma
Mary Steinbach,(1) DNP, APRN, Kathleen Colson,(2) RN, BSN, BS, and Beth Faiman,(3) PhD, MSN, APRN-BC, AOCN®, BMTCN, FAANRead MoreGrand Rounds
A Focus on CAR T-Cell Therapy and Bispecific Antibodies in Multiple Myeloma
Donna Catamero, ANP-BC, OCN®, CCRC, Tiffany Richards, PhD, ANP-BC, AOCNP®, and Beth Faiman,(3) PhD, MSN, APRN-BC, AOCN®, BMTCN, FAANRead MoreGrand Rounds
A Focus on Waldenström Macroglobulinemia and AL Amyloidosis
Rebecca Lu, MS, FNP, and Tiffany Richards, PhD, ANP-BC, AOCNP®Read MoreHemophilia A: Strategies for Improving Long-Term Holistic Management, Adherence, and Quality of Life
This educational activity reviews currently approved prophylaxis therapy in hemophilia A, the benefits of prophylaxis and adherence, and patient quality-of-life factors. Interprofessional perspectives from an expert faculty panel are featured.
Faculty
Miguel A. Escobar, MD
Medicine and Pediatrics at the University of Texas Health Science Center
Gulf States Hemophilia & Thrombophilia Center
Houston, Texas
Cindy Leissinger, MD
Tulane University School of Medicine
the Louisiana Center for Bleeding and Clotting Disorders
New Orleans, Louisiana
Guy Young, MD
the Hemostasis & Thrombosis Center
Children’s Hospital Los Angeles
the University of Southern California, Keck School of Medicine
Los Angeles, California
This activity is supported by an educational grant from Genentech, a member of the Roche Group
Continuing Education
Continuing Education Information: Hemophilia A: Strategies for Improving Long-Term Holistic Management, Adherence, and Quality of Life
Read MoreReview Article
Hemophilia A: Strategies for Improving Long-Term Holistic Management, Adherence, and Quality of Life
Miguel A. Escobar,(1) MD, Cindy Leissinger,(2) MD, and Guy Young,(3) MDRead MoreASH Highlights and Commentary: The Advanced Practitioner Perspective
Selected abstracts from the 63rd Annual Meeting of the American Society of Hematology
This supplement to JADPRO provides an overview of several abstracts that were presented at the 2021 ASH Annual Meeting, which took place as a hybrid event in Atlanta, Georgia, from December 11–14, 2021. The overviews are accompanied by expert commentary that aims to contextualize the information presented at ASH for the advanced practitioner (AP).
Guest Editor
Sandra E. Kurtin, PhD, ANP-C, AOCN®
The University of Arizona Cancer Center
Lindsey Lyle, MS, PA-C
University of Colorado Anschutz Medical Campus
Kathryn T. Maples, PharmD, BCOP
Winship Cancer Institute of Emory University
Editorial
Incorporating Scientific Advances and Improving Access to Care: Meeting Abstracts From the 2021 ASH Annual Meeting and Exposition
Sandra E. Kurtin, PhD, ANP-C, AOCN®Read MoreMeeting Abstract
ASH Highlights and Commentary: Multiple Myeloma
Kathryn T. Maples, PharmD, BCOPRead MoreMeeting Abstract
ASH Highlights and Commentary: Myeloid Malignancies
Lindsey Lyle, MS, PA-CRead MoreMeeting Abstract
ASH Highlights and Commentary: Additional Topics of Interest
Sandra E. Kurtin, PhD, ANP-C, AOCN®Read MoreSOHO Highlights and Commentary: The Advanced Practitioner Perspective
Selected Presentations From the 9th Annual Meeting of the Society of Hematologic Oncology
This supplement to JADPRO provides an overview of presentations from the 2021 Annual Meeting of the Society of Hematologic Oncology (September 8–11), along with expert commentary that aims to contexualize the information presented at SOHO for the advanced practitioner.
Guest Editor
Alexis C. Geppner, MLS, CTTS, PA-C
The University of Texas MD Anderson Cancer Center
Lisa Nodzon, PhD, ARNP, AOCNP®
H. Lee Moffitt Cancer Center and Research Institute
Kelly Valla, PharmD, BCOP
Winship Cancer Institute of Emory University
Editorial
The Advanced Practitioner’s Role in Treating Patients With Hematologic Malignancies: Highlights From SOHO 2021
Alexis C. Geppner, MLS, CTTS, MPAS, PA-C, Guest EditorRead MoreMeeting Report
Beyond Hyper-CVAD in ALL: Highlights From SOHO 2021
Alexis C. Geppner, MLS, CTTS, PA-CRead MoreMeeting Report
IDH-Mutated AML: Beyond Enasidenib and Ivosidenib Monotherapy: Highlights From SOHO 2021
Alexis C. Geppner, MLS, CTTS, PA-CRead MoreMeeting Report
Targeting p53 in MDS: Highlights From SOHO 2021
Alexis C. Geppner, MLS, CTTS, PA-CRead MoreMeeting Report
Updates on Clinical Trials for Myelofibrosis: Highlights From SOHO 2021
Lisa Nodzon, PhD, APRN, AOCNP®Read MoreMeeting Report
Therapeutic Updates for Richter Syndrome: Highlights From SOHO 2021
Lisa Nodzon PhD, APRN, AOCNP®Read MoreMeeting Report
BCMA-Directed CAR T Cells in Relapsed Refractory Multiple Myeloma: Highlights From SOHO 2021
Lisa Nodzon PhD, APRN, AOCNP®Read MoreMeeting Report
Immunotherapy Approaches in T-Cell Lymphoma: Highlights From SOHO 2021
Kelly Valla, PharmD, BCOPRead MoreMeeting Report
The Next Wave of Novel Agents in Aggressive B-Cell Lymphoma: Highlights From SOHO 2021
Kelly Valla, PharmD, BCOPRead MoreMeeting Report
Novel Treatment Approaches in Relapsed/Refractory Mantle Cell Lymphoma: Highlights From SOHO 2021
Kelly Valla, PharmD, BCOPRead MoreCDK4/6 Inhibitors: Paving the Way for HR-Positive, HER2-Negative Early Breast Cancer
This supplement to JADPRO reviews the latest emerging evidence for CDK4/6 inhibitors in the adjuvant setting for early breast cancer. Interprofessional perspectives and recommendations for improving adherence and side effect management are featured.
Faculty
Kristi K. Orbaugh, MSN, NP, AOCN®
Community Hospital Oncology Physicians
Zionsville, Indiana
Val R. Adams, PharmD, FCCP, BCOP, FHOPA
Markey Cancer Center at the University of Kentucky
Lexington, Kentucky
Theresa W. Gillespie, PhD, MA, RN, FAAN
Emory University School of Medicine
Winship Cancer Institute
Atlanta, Georgia
This activity is supported by an educational grant from Lilly. For further information concerning Lilly grant funding visit www.lillygrantoffice.com
Review Article
CDK4/6 Inhibitors: Paving the Way for HR-Positive, HER2-Negative Early Breast Cancer
Kristi Orbaugh,(1) RN, MSN, RNP, AOCN®, Val R. Adams,(2) PharmD, FCCP, BCOP, FHOPA, and Theresa W. Gillespie,(3) PhD, MA, RN, FAANRead MoreASH Highlights and Commentary: The Advanced Practitioner Perspective
Selected abstracts from the 62nd Annual Meeting of the American Society of Hematology
This supplement to JADPRO provides an overview of several abstracts that were presented at the 2020 ASH Annual Meeting, along with expert commentary that aims to contextualize the information presented at ASH for the advanced practitioner.
Guest Editor
Sandra E. Kurtin, PhD, ANP-C, AOCN®
The University of Arizona Cancer Center
Beth Faiman, PhD, MSN, APRN-BC, AOCN®, FAAN
Cleveland Clinic
Sara Tinsley, PhD, APRN, AOCN®
Moffitt Cancer Center and Research Institute
Editorial
Reimagining Medical Education: Selected Abstracts From the 2020 ASH Meeting
Sandra E. Kurtin, PhD, ANP-C, AOCN®Read MoreMeeting Abstract
ASH Highlights and Commentary: Multiple Myeloma
Read MoreMeeting Abstract
ASH Highlights and Commentary: Chronic Lymphocytic Leukemia and Lymphomas
Read MoreMeeting Abstract
ASH Highlights and Commentary: Additional Topics of Interest
Read MoreTHE STATUS OF CHEMOTHERAPY IN METASTATIC BREAST CANCER: INSIGHTS FOR THE ADVANCED PRACTITIONER
This supplement to JADPRO provides the latest updates in the use of chemotherapy in metastatic breast cancer with patient-focused implications for advanced practice.
Guest Editors
Kirollos Hanna, PharmD, BCPS, BCOP
Mayo Clinic and M Health Fairview
Kelley Mayden, MSN, FNP, AOCNP
Ballad Health Cancer Care-Brisol
Editorial
The Status of Chemotherapy in Metastatic Breast Cancer: Insights for the Advanced Practitioner
Kirollos Hanna,(1) PharmD, BCPS, BCOP, and Kelley Mayden,(2) MSN, FNP, AOCNP®Read MoreReview Article
Chemotherapy Treatment Considerations in Metastatic Breast Cancer
Kirollos Hanna,(1) PharmD, BCPS, BCOP, and Kelley Mayden,(2) MSN, FNP, AOCNP®Read MoreReview Article
The Use of Real-World Evidence for Oral Chemotherapies in Breast Cancer
Kirollos Hanna,(1) PharmD, BCPS, BCOP, and Kelley Mayden,(2) MSN, FNP, AOCNP®Read MoreSOHO Highlights and Commentary: The Advanced Practitioner Perspective
Selected Presentations From the 8th Annual Meeting of the Society of Hematologic Oncology
This supplement to JADPRO provides an overview of presentations from the 2020 Annual Meeting of the Society of Hematologic Oncology (September 9–12), along with expert commentary that aims to contexualize the information presented at SOHO for the advanced practitioner.
Guest Editor
Allyson Price, MPAS, PA-C
The University of Texas MD Anderson Cancer Center
Lisa Nodzon, PhD, ARNP, AOCNP®
H. Lee Moffitt Cancer Center and Research Institute
Kelly Valla, PharmD, BCOP
Winship Cancer Institute of Emory University
Editorial
The Advanced Practitioner’s Role in Treating Patients With Hematologic Malignancies: Highlights From SOHO 2020
Allyson Price, MPAS, PA-C, Guest EditorRead MoreMeeting Report
Predicting Drug Response in Acute Lymphoblastic Leukemia: Highlights From SOHO 2020
Allyson Price, MPAS, PA-CRead MoreMeeting Report
Immunotherapy for T-Cell ALL and T-NHL: Highlights From SOHO 2020
Allyson Price, MPAS, PA-CRead MoreMeeting Report
Oral Hypomethylating Agents for Myelodysplastic Syndromes: Highlights From SOHO 2020
Allyson Price, MPAS, PA-CRead MoreMeeting Report
Emerging Therapies in Myelofibrosis: Highlights From SOHO 2020
Lisa Nodzon, PhD, ARNP, AOCNP®Read MoreMeeting Report
Updates on Therapeutic Advancements in Relapsed or Refractory Multiple Myeloma: Highlights From SOHO 2020
Lisa Nodzon, PhD, APRN, AOCNP®Read MoreMeeting Report
Minimal Residual Disease in Chronic Lymphocytic Leukemia: Highlights From SOHO 2020
Lisa Nodzon, PhD, ARNP, AOCNP®Read MoreMeeting Report
Integrating Novel Agents in Relapsed or Refractory Hodgkin Lymphoma: Highlights From SOHO 2020
Kelly Valla, PharmD, BCOPRead MoreMeeting Report
Managing Relapsed Disease in Peripheral T-Cell Lymphoma: Highlights From SOHO 2020
Kelly Valla, PharmD, BCOPRead MoreMeeting Report
New CAR Designs: Highlights From SOHO 2020
Kelly Valla, PharmD, BCOPRead MoreManagement of Thrombosis in Polycythemia Vera: The Advanced Practitioner Perspective
This supplement to JADPRO explores two real-life cases of thrombosis in the setting of underlying polycythemia vera.
Guest Editor
Lindsey Lyle, MS, PA-C
University of Colorado Cancer Center
Lindsey E. Kalhagen, PA
Northwestern Medicine
Julie Huynh-Lu, PA
The University of Texas MD Anderson Cancer Center
Editorial
Managing Thrombosis in Polycythemia Vera: The Advanced Practitioner Perspective
Lindsey Lyle, MS, PA-C, Guest EditorRead MoreGrand Rounds
Budd-Chiari Syndrome as Initial Manifestation of Polycythemia Vera: Complexities in the Management of Younger Patients
Lindsey Lyle,(1) MS, PA-C, and Lindsey E. Kalhagen,(2) PARead MoreGrand Rounds
Optimizing Treatment Strategies in Patients With Polycythemia Vera Who Develop a Thrombotic Event on Frontline Therapy
Lindsey Lyle,(1) MS, PA-C, and Julie Huynh-Lu,(2) PARead MoreASH Highlights and Commentary: The Advanced Practitioner Perspective
Selected abstracts from the 61st Annual Meeting of the American Society of Hematology
This supplement to JADPRO provides an overview of several abstracts that were presented at the 2019 ASH Annual Meeting, along with expert commentary that aims to contextualize the information presented at ASH for the advanced practitioner.
Guest Editor
Sandra E. Kurtin, PhD, ANP-C, AOCN®
The University of Arizona Cancer Center
Amy Pierre, ANP-BC
Memorial Sloan Kettering Cancer Center
Sara Tinsley, PhD, APRN, AOCN®
Moffitt Cancer Center and Research Institute
Editorial
The Advanced Practitioner’s Role in Treating Older Adults With Hematologic Malignancies
Sandra E. Kurtin, PhD, ANP-C, AOCN®Read MoreMeeting Abstract
ASH Highlights and Commentary: Chronic Lymphocytic Leukemia
Read MoreMeeting Abstract
ASH Highlights and Commentary: Acute Myeloid Leukemia and Myelodysplastic Syndromes
Read MoreMeeting Abstract
ASH Highlights and Commentary: Multiple Myeloma
Read MoreOptimizing Treatment and Improving Outcomes for Patients With Acute Myeloid Leukemia: A Guide for Advanced Practitioners
A continuing education activity for nurse practitioners, PAs, clinical nurse specialists, advanced degree nurses, oncology and hematology nurses, pharmacists, and physicians.
This certified activity is supported by educational grants from Agios Pharmaceuticals, Inc. and Jazz Pharmaceuticals, Inc.
Editorial
Acute Myeloid Leukemia: An Ever-Changing Disease
Nancy M. Nix, PharmD, BCPS, BCOP, and Allyson Price, MPAS, PA-CRead MoreReview Article
Optimizing Use of Newly Approved Agents for Acute Myeloid Leukemia
Nancy M. Nix, PharmD, BCPS, BCOP, and Allyson Price, MPAS, PA-CRead MoreReview Article
The Role of the Advanced Practitioner in Enhancing Outcomes
Nancy M. Nix, PharmD, BCPS, BCOP, and Allyson Price, MPAS, PA-CRead MoreAppendix
Appendix: Key Information on Newly Approved AML Drugs
Nancy M. Nix, PharmD, BCPS, BCOP, and Allyson Price, MPAS, PA-CRead MoreCAR T-Cell Therapy for Large B-Cell Lymphoma
Practical information for the advanced practitioner on a revolutionary cancer treatment
This supplement to JADPRO, developed in partnership with Nexus Global Group Science LLC, aims to provide practical information to advanced practitioners on a number of considerations when implementing CAR T-cell therapy. It is sponsored by Kite, a Gilead Company.
Editorial
CAR T-Cell Therapy for Large B-Cell Lymphoma
Maritza C. Alencar, DNP, MBA, APRN-BC, BMTCN®Read MoreReview Article
Anti-CD19 CAR T-Cell Therapy for Adult Patients With Refractory Large B-Cell Lymphoma
Kathleen McDermott, RN, BSN, OCN®, BMTCN®, and Lauren Spendley, AGNP, MSN, AOCN®Read MoreReview Article
CAR T-Cell Therapy: Adverse Events and Management
Sherry Adkins, RN, MSN, ANP-CRead MoreReview Article
Educating Multidisciplinary Care Teams, Patients, and Caregivers on CAR T-Cell Therapy
Alix Beaupierre, RN, BSN, OCN®, Nicole Kahle, MS, RN, OCN®, BMTCN®, Rachel Lundberg, PA-C, MPAS, and Amy Patterson, MSN, APRN, AOCNS®, BMTCN®Read MoreASH Highlights and Commentary:
The Advanced Practitioner Perspective
Selected abstracts from the 60th Annual Meeting of the American Society of Hematology
This supplement to JADPRO provides an overview of several abstracts that were presented at the 2018 ASH Annual Meeting, along with expert commentary that aims to contextualize the information presented at ASH for the advanced practitioner.
Guest Editor
Sandra E. Kurtin, PhD, ANP-C, AOCN®
The University of Arizona Cancer Center
Josh Epworth, ARNP
University of Washington
Lindsey Lyle, MS, PA-C
University of Colorado, Anschutz Medical Campus
Editorial
A Letter From the Guest Editor
Sandra E. Kurtin, PhD, ANP-C, AOCN®Read MoreCommentary
ASH Highlights and Commentary: Multiple Myeloma
Josh Epworth, ARNPRead MoreCommentary
ASH Highlights and Commentary: Acute Myeloid Leukemia
Lindsey Lyle, MS, PA-CRead MoreCommentary
ASH Highlights and Commentary: Leukemias and Lymphomas
Sandra E. Kurtin, PhD, ANP-C, AOCN®Read MoreImmuno-Oncology Therapy Essentials: Proactive Management of Immune-Related Adverse Events
This supplement, certified for CME/CE/CPE credit, is jointly provided by:
Editorial
Immuno-Oncology Essentials: An Overview
Brianna Hoffner, MSN, ANP-BC, AOCNP®Read MoreReview Article
Meeting the Challenge of Immune-Related Adverse Events With Optimized Telephone Triage and Dedicated Oncology Acute Care
Brianna Hoffner, MSN, ANP-BC, AOCNP®, and Krista M. Rubin, MS, FNP-BCRead MoreReview Article
PD-1/PD-L1 Inhibitors for Non–Small Cell Lung Cancer: Incorporating Care Step Pathways for Effective Side-Effect Management
Marianne J. Davies, DNP, MSN, RN, APRN, CNS-BC, ACNP-BC, AOCNP®Read MoreReview Article
Checkpoint Inhibitor Immunotherapy for Head and Neck Cancer: Incorporating Care Step Pathways for Effective Side-Effect Management
Casey Fazer, PA-CRead MoreReview Article
Immune-Related Adverse Events From Immunotherapy: Incorporating Care Step Pathways to Improve Management Across Tumor Types
Laura S. Wood, RN, MSN, OCN®Read MoreAppendix
Care Step Pathway Tools for Immune-Related Adverse Event Assessment and Management
Read MoreUnderstanding the Role of Targets and Pathways in the Treatment of Melanoma
This CME/CE/CPE certified supplement is jointly provided by:
Editorial
A Letter From the Guest Editors
Lisa A. Kottschade, APRN, MSN, CNP, and LeAnn B. Norris, PharmD, FCCP, BCPS, BCOPRead MoreEditorial
A Brighter Future for Patients With Melanoma
Lisa A. Kottschade, APRN, MSN, CNP, and LeAnn B. Norris, PharmD, FCCP, BCPS, BCOPRead MoreReview Article
Diagnosis, Evaluation, and Surgical Management of Melanoma
Brianna Hoffner, MSN, ANP-BC, AOCNP®, and Christan G. Bartsch, MSHS, PA-C, MPHRead MoreReview Article
Harnessing the Immune System in the Treatment of Melanoma
Suzanne McGettigan, MSN, CRNP, AOCN®Read MoreReview Article
BRAF/MEK Inhibition in Melanoma: An Update
Lisa A. Kottschade, APRN, MSN, CNP, and Kathleen M. Madden, RN, MSN, FNP-BC, AOCNP®, APHNRead MoreReview Article
Mutations Beyond BRAF V600
Mollie Reed, MSN, ACNP-BCRead MoreReview Article
Melanomas of Noncutaneous Origin: Diagnosis, Treatment, and Outcomes
Lisa A. Kottschade, APRN, MSN, CNPRead MoreReview Article
Supportive Care and Management of Treatment-Related Adverse Effects From Immune Checkpoint Inhibitors and Targeted Therapies in Melanoma
Krista M. Rubin, MS, FNP-BC, and Lisa A. Kottschade, APRN, MSN, CNPRead MoreReview Article
Drug-Drug Interactions in Melanoma
LeAnn B. Norris, PharmD, FCCP, BCPS, BCOPRead MoreAppendix
Appendix
Compiled by Lisa A. Kottschade, APRN, MSN, CNPRead MoreUnderstanding the Role of Targets and Pathways in the Treatment of Chronic Lymphocytic Leukemia
Although this activity has expired, you may still view the supplement content. However, you will not be able to obtain CE credit.
This CME/CE/CPE accredited supplement is jointly provided by:
Faculty
Christopher Arp, PharmD, Levine Cancer Institute—Carolinas HealthCare System, Department of Pharmacy
Kristan Augustin, PharmD, BCOP, Barnes-Jewish Hospital, Department of Pharmacy
Hani M. Babiker, MD, University of Arizona College of Medicine, Translational Genomics Research Institute, and University of Arizona Cancer Center
Andrew Garcia, PharmD, The University of Arizona Cancer Center
Ashley E. Glode, PharmD, BCOP, Department of Clinical Pharmacy, University of Colorado Skaggs School of Pharmacy and Pharmaceutical Sciences
Amy Goodrich, MSN, CRNP, Johns Hopkins School of Medicine and The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Alyssa Hinchman, PharmD, The University of Arizona Cancer Center
Lindsay Hladnik, PharmD, BCOP, Washington University in Saint Louis School of Medicine, Department of Medicine
Nadia Khan, MD, Fox Chase Cancer Center
Sandra E. Kurtin, PhDc, ANP-C, AOCN®, The University of Arizona Cancer Center
Ali McBride, PharmD, BCOP, The University of Arizona Cancer Center
Lisa Nodzon, PhD, ARNP, AOCNP®, Department of Malignant Hematology, Moffitt Cancer Center
Javier Pinilla-Ibarz, MD, PhD, Department of Malignant Hematology, Moffitt Cancer Center
Barbara Barnes Rogers, CRNP, MN, AOCN®, ANP-BC, Fox Chase Cancer Center
Nina Wagner-Johnston, MD, Johns Hopkins School of Medicine and The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
This activity is supported by unrestricted educational grants from
Gilead Sciences Inc. and Pharmacyclics LLC, an AbbVie Company and
Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC.
Continuing Education
Continuing Education Information
Read MoreEditorial
A Letter From the Guest Editors
Sandra E. Kurtin, PhDc, ANP-C, AOCN®, and Ali McBride, PharmD, BCOPRead MoreContinuing Education
Chronic Lymphocytic Leukemia in 2018: What the Advanced Practitioner in Oncology Needs to Know
Sandra E. Kurtin, PhDc, ANP-C, AOCN®, and Ali McBride, PharmD, BCOPRead MoreReview Article
Scientific Advances in the Diagnosis and Risk Stratification of Chronic Lymphocytic Leukemia
Amy Goodrich, MSN, CRNP, and Nina Wagner-Johnston, MDRead MoreReview Article
Monoclonal Antibodies in Chronic Lymphocytic Leukemia
Lindsay Hladnik,(1) PharmD, BCOP, Kristan Augustin,(2) PharmD, BCOP, and Christopher Arp,(3) PharmDRead MoreReview Article
Small Molecules in Chronic Lymphocytic Leukemia: Novel Targets, New Challenges
Sandra E. Kurtin, PhDc, ANP-C, AOCN®, and Ali McBride, PharmD, BCOPRead MoreReview Article
Emerging Therapies in Chronic Lymphocytic Leukemia: Current Trials
Ashley E. Glode, PharmD, BCOP, and Hani M. Babiker, MDRead MoreReview Article
Risk-Adapted Treatment Strategies for Chronic Lymphocytic Leukemia
Lisa Nodzon, PhD, ARNP, AOCNP®, and Javier Pinilla-Ibarz, MD, PhDRead MoreReview Article
Supportive Care and Management of Treatment-Emergent Adverse Events in Chronic Lymphocytic Leukemia
Barbara Barnes Rogers, CRNP, MN, AOCN®, ANP-BC, and Nadia Khan, MDRead MoreReview Article
The Older Adult Living With Chronic Lymphocytic Leukemia: Implications for Oncology Providers, Patients, and Caregivers
Sandra E. Kurtin, PhDc, ANP-C, AOCN®Read MoreAppendix
Appendix
Compiled by Ali McBride, PharmD, BCOP, Andrew Garcia, PharmD, and Alyssa Hinchman, PharmDRead MoreThe Role of the Advanced Practitioner in Maintaining Adherence in Patients on Oral Oncolytics
Although this activity has expired, you may still view the supplement content. However, you will not be able to obtain CE credit.
This CME/CE/CPE accredited supplement is jointly provided by:
Faculty
Diane Cope, PhD, ARNP-BC, AOCNP®, Florida Cancer Specialists and Research Institute
Kimberly M. Hicks, PharmD, MHA, HHCS Health Group of Companies
John Novak, CHA, PA-C, Rocky Mountain Cancer Centers and University of Colorado School of Medicine
Susan Scherer, RN, BSN, OCN®, RN Cancer Guides Solutions
This activity is supported by unrestricted educational grants from AstraZeneca; Bayer HealthCare Pharmaceuticals Inc.; Pharmacyclics LLC, an AbbVie Company and Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC; Novartis Pharmaceutical Corporation; and Taiho Oncology, Inc.
Continuing Education
Continuing Education Information
Read MoreEditorial
A Letter From The Guest Editor
Read MoreReview Article
The Role of the Advanced Practitioner in Maintaining Adherence in Patients on Oral Oncolytics
Kimberly M. Hicks,(1) PharmD, MHA, Diane Cope,(2) PhD, ARNP-BC, AOCNP®, John Novak,(3) CHA, PA-C, and Susan Scherer,(4) RN, BSN, OCNRead MoreThe Emerging Role of Molecular Testing in Ovarian Cancer
Although this activity has expired, you may still view the supplement content. However, you will not be able to obtain CE credit.
This CME/CEU accredited supplement is jointly provided by:
Faculty
Courtney B. Cortez, NP, Indiana University Simon Cancer Center—IU Health
Cynthia L. Hunter, MS, LCGC, Indiana University Health
Patrick J. Kiel, PharmD, BCPS, BCOP, Indiana University School of Medicine, Indiana University Simon Cancer Center—IU Health
Jeanne M. Schilder, MD, Indiana University School of Medicine, Indiana University Simon Cancer Center—IU Health
This supplement is supported by an educational grant from AstraZeneca.
Continuing Education
Continuing Education Information
Read MoreEditorial
The Rise of Genetic Testing in Managing Patients With Ovarian Cancer
Patrick J. Kiel, PharmD, BCPS, BCOPRead MoreReview Article
The Emerging Role of Molecular Testing in Ovarian Cancer
Patrick J. Kiel,(1) PharmD, BCPS, BCOP, Courtney B. Cortez,(2) NP, Cynthia L. Hunter,(3) MS, LCGC, and Jeanne M. Schilder,(1) MDRead MoreThe Emerging Role of Molecular Testing in Non–Small Cell Lung Cancer
Although this activity has expired, you may still view the supplement content. However, you will not be able to obtain CE credit.
This CME/CEU accredited supplement is jointly provided by:
Faculty
Liang Cheng, MD, Indiana University School of Medicine
Gregory Durm, MD, Indiana University Simon Cancer Center—IU Health
Patrick J. Kiel, PharmD, BCPS, BCOP, Indiana University School of Medicine, Indiana University Simon Cancer Center—IU Health
Anna Livers-Ertel, ANP-BC, MSN, OCN®, Franciscan Health Cancer Center
This supplement is supported by an educational grant from AstraZeneca.
Continuing Education
Continuing Education Information
Read MoreEditorial
The Rise of Genetic Testing in Managing Patients With Non–Small Cell Lung Cancer
Patrick J. Kiel, PharmD, BCPS, BCOPRead MoreReview Article
The Emerging Role of Molecular Testing in Non–Small Cell Lung Cancer
Patrick J. Kiel,(1),(2) PharmD, BCPS, BCOP, Liang Cheng,(1) MD, Anna Livers-Ertel,(3) ANP-BC, MSN, OCN®, and Gregory Durm,(2) MDRead MoreGenetic Counseling in Gynecologic Oncology: What Advanced Practitioners Need to Know
Although this activity has expired, you may still view the supplement content. However, you will not be able to obtain CE credit.
This CME/CEU accredited supplement is jointly provided by:
Faculty
Heather Hampel, MS, LGC
The Ohio State University Comprehensive Cancer Center
Brianna Hoffner, MSN, ANP-BC, AOCNP®
University of Colorado Cancer Center
Leigha Senter-Jamieson, MS, LGC
The Ohio State University Wexner Medical Center
Paula Anastasia, RN, MN, AOCN®
Cedars-Sinai Medical Center
This supplement is supported by an independent educational grant from AstraZeneca Pharmaceuticals LP
Editorial
Introduction
Heather Hampel, MS, LGC, Guest EditorRead MoreContinuing Education
Continuing Education Information
Read MoreReview Article
Lynch Syndrome and Immunotherapy
Heather Hampel, MS, LGC, and Brianna Hoffner, MSN, ANP-BC, AOCNP®Read MoreReview Article
BRCA-Related Ovarian Cancers and the Role of PARP Inhibitor Therapy
Leigha Senter, MS, LGC, and Paula Anastasia, RN, MN, AOCN®Read MoreThe Latest Advances in CAR T-Cell Therapy for Refractory and Relapsed Lymphomas and Leukemias
Although this activity has expired, you may still view the supplement content. However, you will not be able to obtain CE credit.
Faculty
Marco L. Davila, MD, PhD
Associate Member
Department of Blood and Marrow Transplantation
H. Lee Moffitt Cancer Center and Research Institute
Tampa, Florida
This activity is supported by an educational grant from Kite Pharma, Inc.
Continuing Education
Continuing Education Information
Read MoreContinuing Education
CAR T-Cell Therapy: An Approach Whose Time Has Come
Read MoreContinuing Education
The Latest Advances in CAR T-Cell Therapy for Refractory and Relapsed Lymphomas and Leukemias
Marco L. Davila, MD, PhDRead MoreUnderstanding the Role of Targets and Pathways in the Treatment of Non–Small Cell Lung Cancer
Although this activity has expired, you may still view the supplement content. However, you will not be able to obtain CE credit.
A continuing education article for physicians, PAs, doctors of nursing practice, nurse practitioners, advanced practice nurses including clinical nurse specialists, and other advanced degree nurses.
Faculty
Lisa Cordes, PharmD, BCACP, BCOP, National Institutes of Health
Sandra Cuellar, PharmD, BCOP, University of Illinois Hospital and Health Sciences System—Pharmacy Practice
Marianne Davies, DNP, MSN, CNS, ACNP, AOCNP®, Yale University School of Nursing
Beth Eaby-Sandy, MSN, CRNP, OCN®, Abramson Cancer Center, Hospital of the University of Pennsylvania
Clell Hasenbank, PharmD, Providence St Mary Regional Cancer Center
Karen Oishi, MSN, APRN, AGPCNP-BC, OCN®, The University of Texas MD Anderson Cancer Center
Melinda Oliver, BA, BSN, RN, MPAP, The University of Texas MD Anderson Cancer Center
Samantha Schmidt, PharmD, Lexington Medical Center
Helen Shih, MSN, MPH, University of California, San Francisco Department of Thoracic Oncology
Grashma Vadakkel, PharmD(c), University of South Florida College of Pharmacy
Elizabeth S. Waxman, RN, MSN, AOCN®, ANP-BC, The University of Texas MD Anderson Cancer Center
This supplement is supported by educational grants from the following companies: Genentech and Merck Sharp & Dohme Corp.
Continuing Education
Continuing Education Information
Read MoreEditorial
Letter From the Guest Editors
Read MoreEditorial
Take a Deep Breath: More Treatment Options for Non–Small Cell Lung Cancer
Lisa Cordes, PharmD, BCACP, BCOP, and Elizabeth S. Waxman, RN, MSN, AOCN®, ANP-BCRead MoreReview Article
Diagnosis of Lung Cancer
Marianne Davies, DNP, MSN, CNS, ACNP, AOCNP®, and Helen Shih, MSN, MPHRead MoreReview Article
Fundamentals of Lung Cancer Staging
Marianne Davies, DNP, MSN, CNS, ACNP, AOCNP®Read MoreReview Article
Predictive and Prognostic Biomarkers and Related Therapies in Non–Small Cell Lung Cancer
Samantha Schmidt, PharmD, and Grashma Vadakkel, PharmD(c)Read MoreReview Article
Supportive Care and Management of Treatment-Emergent Adverse Events With Targeted Therapy in Non–Small Cell Lung Cancer
Clell Hasenbank, PharmDRead MoreReview Article
Emerging Biomarkers in Non–Small Cell Lung Cancer
Melinda Oliver, BA, BSN, RN, MPAPRead MoreReview Article
Immunotherapy Mechanisms of Action in Non–Small Cell Lung Cancer
Beth Eaby-Sandy, MSN, CRNP, OCN®Read MoreReview Article
Unleashing the Immune System With Checkpoint Inhibitors in Non–Small Cell Lung Cancer: Clinical Review of Adverse Events
Sandra Cuellar, PharmD, BCOPRead MoreReview Article
Emerging Therapies in Non–Small Cell Lung Cancer: Clinical Trials With Novel Agents
Karen Oishi, MSN, APRN, AGPCNP-BC, OCN®Read MoreTools and Technology
Resources for Patients With Non–Small Cell Lung Cancer and Their Caregivers and Providers
Elizabeth S. Waxman, RN, MSN, AOCN®, ANP-BCRead MoreAppendix
Appendix
Lisa Cordes, PharmD, BCACP, BCOPRead MoreEditorial
Priming the Pump Task Force
Read MoreManaging the Care of Patients With HER2-Positive Breast Cancer: A Collaborative Practice Model
Although this activity has expired, you may still view the supplement content. However, you will not be able to obtain CE credit.
A continuing education article for physicians, PAs, doctors of nursing practice, nurse practitioners, advanced practice nurses including clinical nurse specialists, and other advanced degree nurses.
Faculty
Angela DeMichele, MD, MSCE, Alan and Jill Miller Endowed Chair in Breast Cancer Excellence and Professor of Medicine and Epidemiology, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA
Jennie Greco Lattimer, MSN, BSN, CRNP, Oncology Nurse Practitioner, University of Pennsylvania Perelman Center for Advanced Medicine, Philadelphia, PA
This supplement is supported by an educational grant from Genentech.
Continuing Education
Continuing Education Information
Read MoreContinuing Education
Meet the Team
Read MoreContinuing Education
Managing the Care of Patients With HER2-Positive Breast Cancer: A Collaborative Practice Model
Angela DeMichele, MD, MSCE; Jennie Greco Lattimer, MSN, BSN, CRNP; and Rachel F.Read MoreAppendix
Appendix
Managing the Care of Patients With HER2-Positive Breast Cancer: A Collaborative Practice ModelRead MoreThe Advanced Practitioner's Guide to Multiple Myeloma
Although this activity has expired, you may still view the supplement content. However, you will not be able to obtain CE credit.
A continuing education activity for nurse practitioners, physician assistants, clinical nurse specialists, advanced degree nurses, oncology and hematology nurses, pharmacists, and physicians.
This CME/CE/CEU accredited supplement is jointly provided by
This supplement has been developed by members of the International Myeloma Foundation Nurse Leadership Board
Faculty
Page Bertolotti, RN, BSN, OCN, Samuel Oschin Cancer Center at Cedars-Sinai Medical Center
Kevin Brigle, PhD, NP, VCUHS Massey Cancer Center
Donna D. Catamero, ANP-BC, OCN, CCRC, Mount Sinai Medical Center
Kathleen Colson, RN, BSN, BS, Dana-Farber Cancer Center
Hollie Devine, MSN, ANP-BC, The Ohio State University Medical Center James Cancer Hospital
Deborah Doss, RN, OCN, Dana-Farber Cancer Center
Beth Faiman, PhD, MSN, APRN-BC, AOCN, Cleveland Clinic Taussig Cancer Institute
Elizabeth Finley-Oliver, RN, BSN, OCN, H. Lee Moffitt Cancer Center and Research Institute
Charise Gleason, MSN, NP-BC, AOCNP, Winship Cancer Institute of Emory University
Sandra Kurtin, RN, MSN, AOCN, ANP-C, The University of Arizona Cancer Center
Patricia A. Mangan, RN, MSN, APRN-BC, Abramson Cancer Center at the University of Pennsylvania
Ali McBride, PharmD, MS, BCPS, BCOP, The University of Arizona Cancer Center
Ann McNeill, RN, MSN, APN, John Theurer Cancer Center at HUMC
Teresa Miceli, RN, BSN, OCN, Mayo Clinic-Rochester
Kimberly Noonan, RN, ANP, AOCN, Dana-Farber Cancer Center
Tiffany Richards, MS, ANP, AOCNP, MD Anderson Cancer Center
Sandra Rome, RN, MN, AOCN, CNS, Cedars-Sinai Medical Center
Joseph Tariman, PhD, ANP-BC, DePaul University
Daniel Verina, BS, BSN, MSN, ACNP-BC, Mount Sinai Medical Center
This supplement is provided by independent educational grants from the following companies: Takeda Oncology, Celgene Corporation, Binding Site, and Adaptive Biotechnologies.
Continuing Education
Continuing Education Information
Read MoreEditorial
The Future is Bright
Sandra Kurtin, RN, MSN, AOCN®, ANP-CRead MoreEditorial
The Continuum of Care in Multiple Myeloma Redefined: Challenges and Opportunities
Sandra Kurtin, RN, MSN, AOCN®, ANP-C, Guest EditorRead MoreReview Article
Sequencing of Treatment and Integration of Clinical Trials
Beth Faiman,(1) PhD, MSN, APRN-BC, AOCN®, Charise Gleason,(2) MSN, NP-BC, AOCNP®, Kathleen Colson,(3) RN, BSN, BS, Ann McNeill,(4) RN, MSN, APN, and Donna Catamero,(5) ANP-BC, OCN®, CCRC, on behalf of the International Myeloma Foundation Nurse Leadership BoardRead MoreReview Article
Palliative Care in Multiple Myeloma
Tiffany Richards,(1) MS, ANP, AOCNP®, and Kevin Brigle,(2) PhD, NP, on behalf of the International Myeloma Foundation Nurse Leadership BoardRead MorePrescriber's Corner
New Agents in the Treatment of Multiple Myeloma
Beth Faiman,(1) PhD, MSN, APRN-BC, AOCN®, Ali McBride,(2) PharmD, MS, BCPS, BCOP, Hollie Devine,(3) MSN, ANP-BC, Charise Gleason,(4) MSN, NP-BC, AOCNP®, and Sandra Kurtin,(5) RN, MSN, AOCN®, ANP-C, on behalf of the International Myeloma Foundation Nurse Leadership BoardRead MorePrescriber's Corner
Monoclonal Antibodies in the Treatment of Multiple Myeloma
Charise Gleason,(1) MSN, NP-BC, AOCNP®, Hollie Devine,(2) MSN, ANP-BC, Beth Faiman,(3) PhD, MSN, APRN-BC, AOCN®, Deborah Doss,(4) RN, OCN®, and Sandra Kurtin,(5) RN, MSN, AOCN®, ANP-C, on behalf of the International Myeloma Foundation Nurse Leadership BoardRead MoreGrand Rounds
Updates in the Diagnosis and Monitoring of Multiple Myeloma
Sandra Kurtin,(1) RN, MSN, AOCN®, ANP-C, Page Bertolotti,(2) RN, BSN, OCN®, Kevin Brigle,(3) PhD, NP, and Daniel Verina,(4) BS, BSN, MSN, ACNP-BC, on behalf of the International Myeloma Foundation Nurse Leadership BoardRead MorePractice Matters
Adherence, Persistence, and Treatment Fatigue in Multiple Myeloma
Sandra Kurtin,(1) RN, MSN, AOCN®, ANP-C, Kathleen Colson,(2) RN, BSN, BS, Joseph Tariman,(3) PhD, ANP-BC, Beth Faiman,(4) PhD, MSN, APRN-BC, AOCN®, and Elizabeth Finley-Oliver,(5) RN, BSN, OCN, on behalf of the International Myeloma Foundation Nurse Leadership BoardRead MoreTools and Technology
Resources for Patients and Caregivers With Multiple Myeloma and Their Providers
Kevin Brigle, PhD, NP, on behalf of The International Myeloma Foundation Nurse Leadership BoardRead MoreAppendix
Multiple Myeloma Treatment Options for Newly Diagnosed, Relapsed, and Refractory Disease
Kimberly Noonan,(1) RN, ANP, AOCN®, Teresa S. Miceli,(2) RN, BSN, OCN®, Patricia Mangan,(3) RN, MSN, APRN-BC, and Sandra Rome,(4) RN, MN, AOCN®, CNS, on behalf of the International Myeloma Foundation Nurse Leadership BoardRead MoreMethotrexate and Fluorouracil Toxicities:
What Advanced Practitioners in Oncology Need to Know
Although this activity has expired, you may still view the supplement content. However, you will not be able to obtain CE credit.
Faculty
Christopher J. Campen, PharmD, BCPS, BCOP, Arizona Cancer Center, University of Arizona
Wendy H. Vogel, MSN, FNP, AOCNP®, Wellmont Cancer Institute
Julie M. Vose, MD, MBA, University of Nebraska Medical Center
Continuing education credit is provided through the Meniscus Educational Institute, a triple accredited provider for CME/CE/CEU credits and contact hours, upon successful completion of the supplement and evaluation.
This activity is supported by an unrestricted educational grant from BTG International.
Continuing Education
Continuing Education Information
Read MoreMeeting Report
Meet The Panel
Read MoreMeeting Abstract
Methotrexate and Fluorouracil Toxicities: What Advanced Practitioners in Oncology Need to Know
Read MoreMeeting Abstract
Case Studies: Collaborative Practice In Action
Read MoreMeeting Abstract
Questions Answered About Glucarpidase
Read MoreMeeting Abstract
Questions Answered About Uridine Triacetate
Read MoreCollaborative Practice Enhances Supportive Care in Cancer: Chemotherapy-Induced Nausea and Vomiting
Although this activity has expired, you may still view the supplement content. However, you will not be able to obtain CE credit.
Faculty
Rita Wickham, PhD, RN, AOCN®, Rush University College of Nursing (Adjunct Faculty)
Sally Barbour, PharmD, BCOP, CPP, Duke University Medical Center
Teresa Scardino, RPA-C, MPAS, Memorial Sloan Kettering Cancer Center
Continuing education credit is provided through the Meniscus Educational Institute, a triple accredited provider for CME/CE/CEU credits and contact hours, upon successful completion of the supplement and evaluation.
Supported by an unrestricted educational grant from Heron Therapeutics (formerly AP Pharma)
Continuing Education
Continuing Education Information
Read MoreEditorial
Collaborative Practice Enhances Supportive Care in Cancer: Chemotherapy-Induced Nausea and Vomiting
Rita Wickham, PhD, RN, AOCN® Sally Barbour, PharmD, BCOP, CPP Teresa Scardino, RPA-C, MPASRead MoreReview Article
Risks for Chemotherapy-Induced Nausea and Vomiting: Capturing Relevant Data
Teresa Scardino, RPA-C, MPASRead MoreReview Article
Actualizing Standards of Care for Chemotherapy-Induced Nausea and Vomiting
Sally Barbour, PharmD, BCOP, CPPRead MoreReview Article
Managing Chemotherapy-Induced Nausea and Vomiting: Past, Present, and Future
Rita Wickham, PhD, RN, AOCN®Read MoreGrand Rounds
Managing Chemotherapy-Induced Nausea and Vomiting: An Adaptable, Collaborative Approach for a Patient With Colon Cancer
Rita Wickham, PhD, RN, AOCN®, Sally Barbour, PharmD, BCOP, CPP, and Teresa Scardino, RPA-C, MPASRead MoreNursing Perspectives on Carfilzomib in Patients With Relapsed or Refractory Multiple Myeloma
Guest Editor
Sandra E. Kurtin, RN, MS, AOCN®, ANP-C
The supplement and associated publication costs were funded by Onyx Pharmaceuticals, Inc. Fishawack Communications, Inc., provided medical writing and editorial assistance, supported by Onyx Pharmaceuticals.
Review Article
Relapsed or Relapsed/Refractory Multiple Myeloma
Sandra E. Kurtin, RN, MS, AOCN®, ANP-CRead MorePrescriber's Corner
Carfilzomib
J. Michael Vozniak, PharmD, BCOPRead MoreReview Article
The Side Effect Profile of Carfilzomib: From Clinical Trials to Clinical Practice
Laura McBride, RN, BSN, OCN®, CCRP, and Christine O. Samuel, RN, BSN, OCN®, CCRPRead MoreGrand Rounds
Treatment of Patients With Multiple Myeloma: A Relapsed and Refractory Case Study
Sandra E. Kurtin, RN, MS, AOCN®, ANP-CRead MoreReview Article
Treatment With Carfilzomib: A Promising Future for Multiple Myeloma
Donna Catamero, ANP-BC, OCN®, CCRC, and Charise Gleason, MSN, ANP, AOCNP®Read MoreMonitoring, Treatment Resistance, and Treatment Failure in Chronic Myeloid Leukemia
Breaking Barriers to Improved Outcomes
Jorge Eduardo Cortes, MD
The University of Texas MD Anderson Cancer Center
Houston, Texas
John M. Goldman, DM, FRCP, FRCPath, FMedSci
Imperial College
London, United Kingdom
Timothy P. Hughes, MD, MBBS
Centre for Cancer Biology
Adelaide, Australia
Faculty Perspectives by:
Patricia S. Ault, RN, FNP, and Mary Beth Rios, CCRP, RN
The University of Texas MD Anderson Cancer Center
Houston, Texas
Although this activity has expired, you may still view the supplement content. However, you will not be able to obtain CE credit.
CNE provided by MediCom Worldwide, Inc.
This activity is supported by an unrestricted educational grant from ARIAD Pharmaceuticals, Inc.
Continuing Education
Continuing Education Information
Read MoreReview Article
Monitoring, Treatment Resistance, and Treatment Failure in CML: Breaking Barriers to Improved Outcomes
Jorge Eduardo Cortes, MD(1). John M. Goldman, DM, FRCP, FRCPath, FMedSci(2), and Timothy P. Hughes, MD, MBBS(3); Faculty Perspectives by Patricia S. Ault, RN, FNP(1), and Mary Beth Rios, CCRP, RN(1)Read MoreProceedings of selected presentations from
2nd Annual Managing Hematologic Malignancies: The Balancing Act
Although this activity has expired, you may still view the supplement content. However, you will not be able to obtain CE credit.
Sandra Kurtin, RN, MS, AOCN®, ANP-C, University of Arizona and Arizona Cancer Center
Jean A. Ridgeway, MSN, APN, NP-C, AOCN®, University of Chicago Medical Center
Amy Goodrich, MSN, CRNP, John Hopkins Kimmel Cancer Center
Elizabeth Bilotti, MSN, RN, APN, OCN®, John Theurer Cancer Center, Hackensack University Medical Center
This activity is designed for oncology NPs, PAs, and CNSs interested in learning more about hematologic malignancies and the management of these patients.
This activity is jointly sponsored by Medical Education Resources, Inc., and Avid Education Partners, LLC.:
Supported by educational grants from Celgene, Cephalon Oncology, and Millennium: The Takeda Oncology Company.
Continuing Education
Continuing Education Information
Read MoreEditorial
Managing Hematologic Malignancies: The Balancing Act
Sandra Kurtin, RN, MS, AOCN®, ANP-CRead MoreReview Article
Current Approaches to the Diagnosis and Management of Myelodysplastic Syndromes
Sandra Kurtin, RN, MS, AOCN®, ANP-CRead MoreReview Article
Risk Stratification and Management of Acute Myeloid Leukemia
Jean A. Ridgeway, MSN, APN, NP-C, AOCN®Read MoreReview Article
Update on the Management of Follicular Lymphomas
Amy Goodrich, MSN, CRNPRead MoreReview Article
Management of Multiple Myeloma and Serious Side Effects
Elizabeth Bilotti, MSN, RN, APN, OCN®Read MoreOral Mucositis: Addressing the Causes, Challenges, and Clinical Management
Although this activity has expired, you may still view the supplement content. However, you will not be able to obtain CE credit.
Carrie F. Daly, MS, RN, AOCN®, Rush University Medical Center
Annette M. Quinn, MSN, RN, University of Pittsburgh Medical Center
Oral mucositis remains one of the most painful and debilitating side effects of cancer therapy. A working knowledge of the risk factors for oral mucositis and oral cavity assessment protocols is essential to early identification of signs and symptoms in high-risk patients. The use of evidence-based guidelines and patient education will facilitate symptom management and supportive care strategies designed to avoid reductions, delays, or discontinuation of cancer treatment.
CE provided by:
Continuing Education
Continuing Education Information
Read MoreReview Article
Oral Mucositis: Addressing the Causes, Challenges, and Clinical Management
Carrie F. Daly, MS, RN, AOCN®, and Annette M. Quinn, MSN, RNRead More